Kun‐Huei Yeh

机构：National Taiwan University, National Taiwan University Hospital · ORCID：0000-0002-7306-174X

发表论文 332 篇 · 总被引 15245 次 · h-index 48

代表论文

• ctDNA-based molecular residual disease and survival in resectable colorectal cancer (2024 · Nature Medicine · 被引 230)
• Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer (2025 · Journal of Clinical Oncology · 被引 44)
• Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study (2025 · Journal of Clinical Oncology · 被引 39)
• A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC): The ALTAIR study. (2025 · Journal of Clinical Oncology · 被引 21)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 20)
• Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial (2025 · The Lancet Oncology · 被引 12)